Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings Inc (MEDP)
:MEDP
MEDP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$250.05 - $501.30
Previous CloseN/A
Volume64.09K
Average Volume (3M)620.78K
Market Cap
$12.09B
Enterprise Value$9.25B
Total Cash (Recent Filing)$46.33M
Total Debt (Recent Filing)$124.95M
Price to Earnings (P/E)31.9
Beta1.18
Next Earnings
Oct 27, 2025EPS Estimate
3.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.10
Shares Outstanding28,093,025
10 Day Avg. Volume547,852
30 Day Avg. Volume620,785
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)12.46
Price to Sales (P/S)4.88
P/FCF Ratio17.97
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue4.14
Enterprise Value/Gross Profit13.11
Enterprise Value/Ebitda18.85
Forecast
1Y Price Target
$411.50Price Target Upside-4.84% Downside
Rating ConsensusHold
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Funding EnvironmentThe current stable and improved funding environment is seen as a supportive factor for MEDP's future operations.
Quarterly PerformanceMEDP's strong quarterly performance exceeded low expectations, contributing to a significant stock price increase.
Revenue OutlookImproved revenue outlook due to clients accelerating decisions, projects starting up more rapidly, and a shift toward faster burning therapeutic areas such as metabolic diseases.
Bears Say
Analyst DowngradeThe analyst downgraded shares of MEDP to Sell from Hold, as the recent 55% move is believed to reflect short covering rather than a material change in fundamentals.
Stock ValuationShares are considered overvalued at 31 times the revised estimates relative to expected growth.
Medpace Holdings News
MEDP FAQ
What was Medpace Holdings Inc’s price range in the past 12 months?
Medpace Holdings Inc lowest stock price was $250.05 and its highest was $501.30 in the past 12 months.
What is Medpace Holdings Inc’s market cap?
Medpace Holdings Inc’s market cap is $12.09B.
When is Medpace Holdings Inc’s upcoming earnings report date?
Medpace Holdings Inc’s upcoming earnings report date is Oct 27, 2025 which is in 80 days.
How were Medpace Holdings Inc’s earnings last quarter?
Medpace Holdings Inc released its earnings results on Jul 21, 2025. The company reported $3.1 earnings per share for the quarter, beating the consensus estimate of $2.983 by $0.117.
Is Medpace Holdings Inc overvalued?
According to Wall Street analysts Medpace Holdings Inc’s price is currently Overvalued.
Does Medpace Holdings Inc pay dividends?
Medpace Holdings Inc does not currently pay dividends.
What is Medpace Holdings Inc’s EPS estimate?
Medpace Holdings Inc’s EPS estimate is 3.53.
How many shares outstanding does Medpace Holdings Inc have?
Medpace Holdings Inc has 28,093,025 shares outstanding.
What happened to Medpace Holdings Inc’s price movement after its last earnings report?
Medpace Holdings Inc reported an EPS of $3.1 in its last earnings report, beating expectations of $2.983. Following the earnings report the stock price went up 54.665%.
Which hedge fund is a major shareholder of Medpace Holdings Inc?
Currently, no hedge funds are holding shares in MEDP
Medpace Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$411.50 (-4.84% Downside)
$411.50 (-4.84% Downside)
Blogger Sentiment
Bullish
MEDP Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.54%
12-Months-Change
Fundamentals
Return on Equity
89.38%
Trailing 12-Months
Asset Growth
-18.14%
Trailing 12-Months
Company Description
Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
MEDP Company Deck
MEDP Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong revenue growth, increased EBITDA, and improved revenue guidance. However, challenges such as decreased backlog, lower win rates, and higher reimbursable costs were noted. The sustainability of growth into 2026 remains uncertain.View all MEDP earnings summariesMEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$411.50
▼(-4.84% Downside)
Technical Analysis
Ownership Overview
20.54% Insiders
23.58% Mutual Funds
3.62% Other Institutional Investors
30.71% Public Companies and
Individual Investors